Companies: 10,795·Total market cap: $144.5T
Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNSNASDAQHealthcare
$0.55
+$0.00(+0.00%)
Market Cap$30370175
P/E Ratio
52W High$10.5
52W Low$0.22
SEC Filings

Marinus Pharmaceuticals, Inc. (MRNS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001267813 · MRNS · NASDAQ · as of Jun 10, 2026

Filing snapshot

652
Total Filings
SCHEDULE 13G/A
Latest Form
2025-05-15
Most Recent
2014
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001267813 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2024-03-05
Fiscal Year End
Mar 5, 2024
Accession No.
0001558370-24-002479
Primary Document
mrns-20231231x10k.htm
Source: data.sec.gov · CIK 0001267813 · Accession 0001558370-24-002479

Latest Key Filings

10-QQuarterly Report
10-Q
2024-11-12
8-KCurrent Report
FORM 8-K
2025-02-11Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-03-06
View
15-12G15-12G
15-12G
2025-02-21
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-14
View
EFFECTEFFECT
EFFECT
2025-02-13
View
EFFECTEFFECT
EFFECT
2025-02-13
View
EFFECTEFFECT
EFFECT
2025-02-13
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-12
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2025-02-11
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-11
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-11
View
25-NSE25-NSE
25-NSE
2025-02-11
View
S-8 POSS-8 POS
S-8 POS
2025-02-11
View
S-8 POSS-8 POS
S-8 POS
2025-02-11
View
Showing 1–15 of 441 filingsForm 4 / 144 hidden· 652 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001267813  |  Exchange: NASDAQ · Healthcare

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) has submitted 652 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001267813, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Marinus Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Marinus Pharmaceuticals, Inc. 10-K was filed on 2024-03-05 for fiscal year ending 2024. Historical MRNS 10-K annual reports are available from 2003 through 2024.

Investors researching Marinus Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10

Frequently Asked Questions

MRNS SEC Filings · 8 questions

Marinus Pharmaceuticals, Inc. (MRNS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 652 filings and access original documents at no cost. Marinus Pharmaceuticals, Inc.'s CIK is 0001267813.

MRNS SEC filingsMarinus Pharmaceuticals, Inc. SEC documentsfind MRNS 10-K